VistaGen says Phase 2 repeat-dose fasedienol study in social anxiety disorder shows favorable safety, efficacy signals

Reuters2026/08/06 12:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

VistaGen released topline results from an exploratory Phase 2 repeat-dose study of fasedienol nasal spray for acute social anxiety triggered by public speaking.
Safety met the study objective, with repeat dosing showing tolerability comparable to a single dose and no new safety issues.
Efficacy signals favored fasedienol over placebo on the main anxiety measure, though the trial was not designed to show statistically significant differences.
A prespecified very severe subgroup showed a nominally significant improvement with fasedienol, supporting FDA discussions on a potential registrational pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

VistaGen says Phase 2 repeat-dose fasedienol study in social anxiety disorder shows favorable safety, efficacy signals

You may also like

Crypto prices